About TreeFrog Therapeutics
TreeFrog Therapeutics is a company based in Talence (France) founded in 2018 by Maxime Feyeux and Kevin Alessandri. TreeFrog Therapeutics has raised $84.25 million across 8 funding rounds from investors including European Investment Bank, Bpifrance and European Union. TreeFrog Therapeutics operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Talence, France
- Founders Maxime Feyeux, Kevin Alessandri
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website treefrog.fr
- Social LinkedIn X YouTube
- Total Equity Funding$84.25M (USD)
in 8 rounds
- Latest Funding Round$34.17M (USD), Debt – Conventional
May 2025
- InvestorsEuropean Investment Bank
& 10 more
Apps and channels of TreeFrog Therapeutics
its YouTube channel TreeFrog Therapeutics has 471 subscribers and 30 videos.
Videos from TreeFrog Therapeutics
The most watched videos on TreeFrog Therapeutics's YouTube channel, TreeFrog Therapeutics (471 subscribers). Click a video to play it here.
More on TreeFrog Therapeutics.
Funding Insights of TreeFrog Therapeutics
TreeFrog Therapeutics has successfully raised a total of $84.25M across 8 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $34.17 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84.25M
- Total Rounds 8
- Last Round Debt – Conventional — $34.17M
- First Round $689,313
(Jan 2019)
- Investors Count 11
All 8 funding rounds of TreeFrog Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $34.17M | Debt – Conventional | – | – | |
| Oct 2021 | $57,804 | Grant | – | – | |
| Sep 2021 | $75.58M | Series B | – | XAnge, Leonard Green and Partners | – |
| Nov 2019 | $2.65M | Grant | – | – | |
| Sep 2019 | $3.3M | Grant | – | – | |
| May 2019 | $7.97M | Series A | – | XAnge | |
| Mar 2019 | $741,510 | Grant | – | – | |
| Jan 2019 | $689,313 | Seed | – | Aquiti Gestion |
11 investors in total: 11 institutional.
Investors in TreeFrog Therapeutics
TreeFrog Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Bpifrance and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Venture capital fund focused on tech companies | – | xange.vc | Paris, France | |
Recapitalizations are targeted through private equity investments by the firm. | – | leonardgreen.com | Los Angeles, United States | |
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Galia Gestion is engaged in private equity investments in southwestern France. | – | galia-gestion.com | Bordeaux, France | |
Early to Growth stage VC & PE firm funding | – | aquiti.fr | Pessac, France | |
Investment services are provided to startups, SMEs, and ETI in South-West France. | 1981 | irdi.fr | Toulouse, France | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Delivers comprehensive financial services solutions. | 2012 | ast-innovations.com | Talence, France |
Investor details for TreeFrog Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TreeFrog Therapeutics
47 people are tracked at TreeFrog Therapeutics (15 in leadership, 17 in board & advisors, 15 in team).
| Name | Role | Group |
|---|---|---|
Maxime Feyeux | Co-Founder & CEO | Leadership |
Kevin Alessandri | Co-Founder & CTO | Leadership |
Frédéric Desdouits | Chief Executive Officer | Leadership |
Michael Lanero Fidalgo | COO | Leadership |
Anthony Renodon | Associate Director Business Development | Leadership |
Kévin Alessandri | Co-Founder, CTO | Leadership |
Daniel Castro | Chief Business Officer | Leadership |
Clément Rieu | Director Of Physics And Technology R&d | Leadership |
Joffrey Mianne | Head Of Ipsc Research | Leadership |
Jérôme Hardoüin | Head of Innovation - Physics | Leadership |
Dan Soto | Director of Technical Operations | Leadership |
Jens Schröder | Chief Medical Officer | Leadership |
Rachel Mooney | Chief Communications Officer | Leadership |
Jaime Arango | CFO | Leadership |
Romain Boiteux | People Director | Leadership |
Jean-Luc Treillou | Chairman | Board & advisors |
Laurent Higueret | Board Member | Board & advisors |
Guilhem de Vregille | Board Member | Board & advisors |
Pete Zippelius | Board Member | Board & advisors |
Justin Eyquem | Scientific Advisor | Board & advisors |
27 more people are available in the full profile.
Complete people profiles for TreeFrog Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TreeFrog Therapeutics
3 dated milestones of TreeFrog Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded TreeFrog Therapeutics is founded.
- Funding First funding round of $689K.
- Funding Latest funding round, Debt – Conventional, of $34.2M.
Competitors of TreeFrog Therapeutics
TreeFrog Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. |
Detailed competitors of TreeFrog Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TreeFrog Therapeutics
The website of TreeFrog Therapeutics (treefrog.fr) receives about 2.9K visits a month and ranks #4,636,263 among all websites worldwide, #5,526 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▼ 14.4% vs previous month
- Unique visitors1.4K
per month
- Global rank#4,636,263
among all websites
- Category rank#5,526
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.2
- Average visit50 sec
- DevicesDesktop 40% · Mobile 60%
Latest news on Treefrog Therapeutics
Complete news archive for TreeFrog Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to TreeFrog Therapeutics
10 companies that operate in the same segment as TreeFrog Therapeutics (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TreeFrog Therapeutics
TreeFrog Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
TreeFrog Therapeutics is headquartered in Talence, France. It is registered at Talence, Nouvelle-aquitaine, France.
Maxime Feyeux is the current CEO of TreeFrog Therapeutics. They have also founded this company.
TreeFrog Therapeutics is a funded company, having raised a total of $84.25M across 8 funding rounds to date. The company's 1st funding round was a Seed of $689.31K, raised on Jan 2019.
TreeFrog Therapeutics is developing stem cells and organoids using proprietary technology to enable the development of cell therapies. It enables the younger cells to mitigate mutational risks. They have developed organoids from pluripotent stem cells.
TreeFrog Therapeutics's top competitors include Merck, Roivant Sciences and AbbVie.
TreeFrog Therapeutics has 11 investors. Key investors include European Investment Bank, Bpifrance, European Union, EIC Fund, and XAnge.